New Hope, United States
Lutonix, Inc., founded in 2007 and headquartered in the United States, operates in the realms of Biotechnology, Health Care, and Medical Devices. The company's flagship product, the Lutonix DCB, is a cutting-edge drug-coated balloon catheter. It is designed to deliver the anti-proliferative agent paclitaxel directly to the arterial wall, maintaining optimal arterial health.
With its innovative design, the Lutonix DCB minimizes systemic exposure to paclitaxel while ensuring that a therapeutic dose efficiently penetrates the arterial wall. This technology distinguishes it from traditional angioplasty options, potentially reducing arterial restenosis risk.
Lutonix last received a $10.00M Series C investment in December 2010. This advancement positions Lutonix as a promising prospect in the medical device landscape, offering significant investment potential to revolutionize arterial health management.
